• news and publications | Enterprise Therapeutics | Treatment of respiratory diseases


Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2019.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more


Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in late 2019.

Learn more